diminishes cholesterol efflux to apoA-I, cholesterol efflux to HDL reduces only by approximately 20%, which could be due to the effect of SR-BI or other unknown mechanisms of cholesterol removal. [17] The ex vivo murine aortic ring assay indicates that loss of ABCG1, alone or in concert with ABCA1, strongly augments neovascularization, [16] which is supportive of ABCG1 as the main transporter responsible for cholesterol removal in ECs. [16] However, all these assays were performed in either an in vitro or ex vivo cell culture system, and thus, there is ample external source of HDL from serum. However, in vivo in zebrafish, knockdown of cholesterol transporter A1 causes a more robust angiogenic sprouting compared to ABCG1 knockdown. [18] It is possible that loss of ABCA1 negates the initial process of generating HDL, which results in no HDL acceptor for ABCG1 to function properly, as reported in mice. [19] [20] [21] [22] In this circumstance, loss of ABCA1 in animals causes a situation similar to ABCA1 and ABCG1 combined deficiency. Consistent with this speculation, loss of ABCA1 in human results in significant reduction of HDL-C levels. [8, 9, 23] Mechanistically, ABCA1 and ABCG1 affect angiogenesis through their ability to modulate the content of cholesterol-rich lipid rafts, which is critical for vascular endothelial growth factor receptor 2 (VEGFR2) signaling. [24] Lipid rafts facilitate VEGFR2 dimerization following vascular endothelial growth factor-A (VEGFA) stimulation, which is an important step for VEGFR2 phosphorylation and signaling. [25] Endocytosis consists of a critical process of prolonged VEGFR2 activation after VEGFA engagement. [26, 27] However, epsin1/2 deficiency, which impairs VEGFR2 endocytosis, paradoxically enhances VEGFR2 signaling. [28] A compensatory pathway may be activated to shunt the endocytosis step for its activation. Alternatively, endocytosis is a double-edge sword that regulates VEGFR2 signaling, which prolongs VEGFR2 activity in the cytosol but diminishes the level of plasma membrane VEGFR2 that can reinitiate another round of VEGF binding and endocytosis. Without endocytosis, in the case of epsin 1/2 deficiency, VEGFR2 may keep transmitting activation signals.
Cav-1, the major scaffolding protein of caveolae, orchestrates angiogenesis in a context-dependent fashion. Cav-1 knockout eliminates endothelial caveolae in mice. [29, 30] Cav-1 deficiency is reported to disrupt cell surface receptor signaling and impair angiogenesis. [31] [32] [33] [34] [35] Consistent with these findings, we and others have shown that decreased caveolae abundance by cholesterol removal inhibits VEGFR2 activation and restricts developmental angiogenesis. [18, 24] Cav-1 depletion, on the other hand, exhibits an proangiogenic effect. For example, Cav-1 knockout mice show greater tumor angiogenesis and hyperpermeability. [36, 37] Cav-1 regulates angiogenesis in part through its interaction with eNOS, [38] [39] [40] the key enzyme for NO production in ECs. eNOS is localized in lipid rafts/caveolae and is essential for the maintenance of vascular tone and angiogenesis. Treatment with L-NAME, an eNOS inhibitor, impairs angiogenesis, [41] and conversely, supplement with NO donor L-arginine enhances neovessel formation in an eNOS-dependent fashion in the hindlimb ischemia model. [42] [43] [44] In addition, VEGFR2 signaling activates eNOS, [45, 46] and reciprocally, forced eNOS expression increases VEGF expression in the blood vessels. [47] In high fat diet-challenged ABCG1 knockout mice, increased Cav-1 and eNOS interaction impairs eNOS activation and attenuates EC function. ABCG1-mediated cholesterol efflux to HDL can reduce Cav-1 and eNOS interaction, thereby alleviating the inhibitory effect of Cav-1 on eNOS and improving EC function. [48] Although lipid rafts often facilitate VEGFR2 signaling, lipid raft disruption by cholesterol removal may have enhancement or inhibitory effects on VEGFR2 signaling. There are several reasons that may account for the discrepancies. First, it is important to ensure that the biological consequence of cholesterol content variance is due to cholesterol proper and not because of the contaminant in chemical (e.g., endotoxin)-induced effects. As such, addition of cholesterol back into cholesterol-depleted cells is a critical control. Second, a possible scenario that accommodates this seemingly contradictory effect on angiogenesis is that, as for many biological events, there may exist a threshold of lipid raft content for optimal VEGFR2 signaling, as in the case of cholesterol effect on Notch signaling [ Figure 1 ], [49] below or above the threshold may have an anti-angiogenic effect. The same may hold true for the different observations of angiogenesis made in Cav1 -/-animals. Another possibility to consider is Cav1-mediated endocytosis, which accordingly adds another layer of complexity to the lipid rafts/caveolae effect on angiogenesis. In addition, cholesterol demonstrates a pleiotropic effect on the lipid bilayer membrane in an in vitro test tube using reconstitution system. [50] Whether these effects occur in vivo requires future investigation.
Recombinant apoA-I, or its mimetic peptides, which accepts plasma membrane cholesterol from the lipid raft microdomains, [51] has been applied to target angiogenesis. [52, 53] We show that apoA-I overexpression corrects accelerated retinal angiogenesis in AIBP knockout mice [ Figure 2 ]. [49] Administration of purified human apoA-I also shows diverse effects on neovessel formation depending on the model system. For example, reconstituted HDL (rHDL) restricts inflammatory angiogenesis while it promotes hypoxia-induced angiogenesis by increasing VEGFA/VEGFR2 expression and activation. [54] In the inflammatory milieu of murine perivascular carotid collar model or tumorigenesis, apoA-I appears to limit angiogenesis [53, 55] whereas apoA-I or rHDL accelerates hypoxia-elicited neovascularization in the murine hindlimb ischemia model. [55] HDL concentration is also a factor of consideration. For example, HDL in the range of 40-80 mg/dL is shown to inhibit in vitro angiogenesis through activation of Rho-associated kinase and inhibition of PI3K/Akt and p38 in endothelial progenitor cells (EPC). [56] HDL receptor SR-BI mediates certain proangiogenic effects of HDL on eNOS activation, cell migration, and in vivo matrigel angiogenesis. [57] In addition, apoA-I also exhibits a stimulatory effect on EC proliferation and angiogenesis through its cell surface receptor F1F0 ATP synthase. [58] lipid RAft-independent effects of lipopRoteins on Angiogenesis HDL exhibits pro-or anti-angiogenic effects on angiogenesis that are not associated with its function in lipid raft disruption. In many studies, the primary effect of HDL on angiogenesis ascribes to its association with bioactive lipid -sphingosine-1-phosphate (S1P). [59] [60] [61] [62] [63] S1P binds apoM, which is present on HDL, and demonstrates distinct biological activities in angiogenesis and vascular integrity. Shear stress augments S1P bioavailability by reducing S1P lyase that decomposes S1P. [64] Mechanistically, S1P binds its receptor, a family of G protein-coupled receptors, and activates PI3K-Akt-eNOS signaling. Endothelial lipase appears to augment the S1P effect on angiogenesis [65] (refer to the detailed review on S1P and vascular function previously published [64] ), but more studies are needed to determine how endothelial lipase enhances S1P function.
In addition to HDL, low-density lipoprotein (LDL) has also been reported to govern angiogenesis. Microsomal triglyceride transfer protein (MTP) mutation that results in low LDL-cholesterol (LDL-C) is found to increase zebrafish angiogenesis. MTP is a lipid transfer protein that assembles apoB-containing very LDL (VLDL) in the liver or chylomicrons in the intestine. [66] The dysregulated angiogenesis phenotype in Mtp mutant animals is due to downregulation of VEGFR1, [67] the decoy receptor for VEGFA, resulting in greater VEGFA availability. The mechanism of how LDL ApoA-I-binding protein-mediated cholesterol removal disrupts lipid rafts/ caveolae, which impairs vascular endothelial growth factor receptor 2 signaling and limits angiogenesis contributes to VEGFR1 upregulation is not clear yet. The pro-angiogenesis effect of Mtp deficiency, however, is not observed in MO-mediated MTP knockdown zebrafish. [68] Although MTP knockdown reduces LDL-C levels, [68] the residual enzyme in the morphants may compensate to an extent that confers insufficient penetration of angiogenesis defects.
Loss of the VLDL receptor in retinas causes excessive angiogenesis in the subretinal space and penetration of blood vessels in the photoreceptor layers. [69, 70] However, usually, VLDL will be catabolized rapidly in the peripheral circulation and cannot enter the brain, thus other apoE-containing lipoproteins that are synthesized de novo in the brain may be responsible for this effect.
Hypercholesterolemia increases EPC counts and promotes reendothelialization. [71] The greater EPC numbers may be due to their differentiation from a higher frequency of HSPCs present in a hypercholesterolemic setting. [13] In vitro cholesterol dose dependently augments EPC function including proliferation, migration, and adhesion and increases proangiogenic VEGFA expression but reduces anti-angiogenic Notch1 expression. [71] ApoA-i-Binding pRotein: A novel pRotein connects cholesteRol efflux with Angiogenesis AIBP, encoded by APOA1BP, is a secreted protein that physically associates with apoA-I and HDL. [72] In addition, AIBP is also localized in the mitochondria and is identified as the epimerase that functions in damaged NAD (P) H repair, where AIBP catalyzes the conversion of R-NAD (P) H-hydrate (NAD [P] HX) to S-NAD (P) HX and an ATP-dependent dehydratase converts the latter to a functional NAD (P) H. [73] [74] [75] [76] [77] [78] AIBP mutation precipitates neurometabolic disorder and lethality in infants, which is hypothesized to be caused by the formation of the presumptive toxic metabolite cyclic NADHX or mitochondrial dysfunction. Loss or mutation of AIBP orthologues in Escherichia coli, Saccharomyces cerevisiae, and Arabidopsis thaliana confers no observable growth phenotype. [73, [76] [77] [78] [79] [80] [81] This is unexpected given the importance and conservation of NAD (P) H metabolism and mitochondrial function. Since the in vivo cause-effect relationship of this enzymatic activity with human pathophysiology is unclear, we prefer to call it AIBP and focus on its cholesterol metabolism function in this review. A recent study suggests a possible moonlight function of an AIBP ortholog in E. coli B6 metabolism, [81] which will need further detailed characterization. AIBP has a paralog, known as YJEFN3 or AIBP2. Aibp2 depletion in zebrafish increases cellular cholesterol content, [18] and this observation is validated in a Genome RNAi screen database using human cells and Drosophila (http://www. genomernai. org/v17/genedetails/2/374887). We identified the role of AIBP in accelerating cholesterol efflux to HDL in ECs. [18] AIBP, by increasing the overall HDL-binding capacity to ECs, but reducing the HDL-binding affinity, creates a situation favoring cholesterol efflux. [18] The AIBP effect on cholesterol efflux to apoA-I is verified in macrophages and is shown to impede lipid raft-associated inflammatory signaling. [82] [83] [84] The mechanism by which AIBP accelerates cholesterol efflux needs further investigation. Ongoing study in our laboratory suggests that AIBP binds ECs in a saturable fashion; [49] thus, we postulate that AIBP binds EC through a yet-to-be identified receptor and mediates targeted cholesterol efflux, which reduces lipid raft/caveolae abundance, inhibits VEGFR2 activation, and limits angiogenesis [ Figure 1 ]. [18, 85] We have characterized the function of AIBP and its zebrafish paralog AIBP2 in blood vessel formation, which may be implicated in preeclampsia and other genetic disorders. [86, 87] Knockdown of AIBP2 in zebrafish increases vascular lipid raft content, bolsters VEGFR2 signaling, and augments angiogenesis in different vascular beds in zebrafish. The absence of cholesterol transporters -Abca1 and Abcg1 phenocopies increases angiogenesis in AIBP2-deficient animals. Conversely, forced AIBP2 expression restricts angiogenic sprouting in an ABCA1-and ABCG1-dependent manner. Raising HDL levels rescues higher membrane lipid order in zebrafish. [18] In line with the zebrafish study, AIBP knockout increases murine retinal angiogenesis in postnatal development, an effect that can be reversed by apoA-I overexpression. [49] Similarly, AIBP deficiency elevates pathological angiogenesis in an in vivo Matrigel angiogenesis model, increases capillary vessel formation, and enhances recovery of perfusion in the hindlimb ischemia model. [49] Mechanistically, AIBP limits angiogenesis through restricting the proangiogenic VEGFR2 activation and enhancing the anti-angiogenic Notch signaling. [18, 49] In contrast to VEGFR2, lipid raft disruption enhances codistribution of Figure 4 : Liver X receptors control angiogenesis through transcription-dependent and transcription-independent effect on angiogenesis. Ligand-engaged liver X receptor α/β heterodimerize with retinoid X receptor and binds ABCG1 promoter and upregulates ABCG1 expression and accelerates cell surface cholesterol removal, thereby reducing plasma membrane lipid raft content and inhibits angiogenesis. Liver X receptor α/β activation also upregulates apoD, which inhibits Akt activation and limits angiogenesis. In addition, liver X receptor β has been shown to interact with ERα, which then activates Akt-eNOS signaling and augments endothelial cell migration and re-endothelialization. HC: Hydroxycholesterol the Notch receptor and its activator protease γ-secretase in nonrafts, which facilitates Notch cleavage and transcriptional activation. While our study in retinal ECs and other studies in neurons show that modest reduction of cholesterol levels increases the products of γ-secretase-mediated proteolytic cleavage, [88] for example, Notch intracellular domain or β amyloid peptide, some studies suggest that lipid rafts augment γ-secretase activity in vitro. [89] Disruption of lipid rafts using 19, 20-dihydroxydocosapentaenoic acid impedes Notch signaling. [90] The extent of lipid raft disruption or optimal content of lipid rafts may account for the disparate observations of Notch activation.
effect of stAtins on Angiogenesis
Statins, HMG CoA reductase inhibitors, are a class of cholesterol-lowering drugs. They reduce plasma LDL-C levels by increasing liver LDL receptor expression.
[91] Interestingly, statins have been reported by multiple studies to regulate angiogenesis. One mechanism is that atorvastatin, when administered at a low concentration (0.01-0.1 µM), bolsters the PI3K-Akt signaling axis, which enhances the migration of EC, thereby increasing angiogenesis. [92, 93] However, high concentrations (>0.1 µM) trigger EC apoptosis, impede EC migration, and suppress angiogenesis. Another study suggests that statins increase HSPC numbers and thus the according differentiation of EPC, an effect that is dependent on greater Akt activation but not on RhoA or eNOS activity [ Figure 3] . [94] Atorvastatin treatment also reduces lipid rafts/ caveolae content, which disrupts the inhibitory effect of Cav-1 on eNOS and bolsters eNOS activity and NO production. [95] While these studies do not show a selectivity of statins on EC type, an interesting study in zebrafish reported that one HMGCR inhibitor, aplexone, selectively inhibits venous but not arterial angiogenesis. At the molecular level, this effect is dependent on geranylgeranylation of Rac and RhoA that preferentially occurs in venous but not arterial ECs. [96] Since Bmp2 expression is the primary signal that controls venous angiogenic sprouting in zebrafish, [97] it is tempting to speculate that a possible crosstalk exists between BMP signaling and cholesterol metabolism, which primes a dependence of protein prenylation for proper venous EC migration.
liveR x ReceptoR α/β tRAnscRiptionAlly oR noncAnonicAlly RegulAtes Angiogenesis
As previously discussed, cholesterol transporters -ABCA1 and ABCG1 regulate angiogenesis, but it is not unexpected that their upstream regulator -LXRα/β also functions in neovascularization [ Figure 4 ]. Indeed, treatment with LXR agonists inhibits EC migration and in vitro angiogenesis. Mechanistically, LXR-induced expression of ABCA1 and ABCG1 augments cholesterol efflux from EC, which disrupts lipid rafts-anchored VEGFR2 signaling. [24] A similar mechanism for LXR-mediated ABCA1-dependent anti-inflammatory effect is proposed in macrophages. [98] A recent study suggests another mechanism for LXR-regulated angiogenesis involving lipoprotein apoD, which is identified as a novel target of LXR. [99] SR-BI is found to interact with apoD and mediate the effect of apoD on angiogenesis, and apoD gain-of-function interferes with Akt and mTOR activation [ Figure 4 ]. [99] In addition, LXRβ has also been reported to modulate angiogenesis independent of transcription activation. [100] In this study, LXRβ interacts with the ERα ligand-binding domain. After PI3K/Akt-mediated phosphorylation at ERα S118, which in turn translocates to the cell surface caveolae, activates eNOS, promotes EC migration, and facilitates carotid artery revascularization in a perivascular injury model [ Figure 4 ]. Since within the caveolae microdomains Cav-1 inhibits eNOS activity, [39, 101, 102] it will be interesting to determine if the extranuclear LXRβ/ ERα complex has any effect on Cav-1 and eNOS interaction. In addition, LXR activation increases VEGFA expression in macrophages and adipose tissue, which is independent of its putative transcription factor HIFa, but instead may be dependent on LXR/retinoid X receptor heterodimer transactivation of VEGFA. [103] The in vivo significance of this pathway is unclear since inflammatory angiogenesis is not affected in mice with LXRs null macrophages.
cholesteRol-modified sonic hedgehog RegulAtes Angiogenesis in A cAnonicAl And noncAnonicAl fAshion
Shh is another cholesterol-regulated pathway for angiogenesis, in which the maturation of the Shh ligand requires cholesterol modification at its C-terminus. [104] Canonical Shh signaling initiates with Shh binding its putative receptor Patched1, which then releases its inhibition of the co-receptor Smoothened and activates transcription factor Gli1-mediated transcriptional events. [105] Shh augments angiogenesis in development and in hindlimb ischemia, which involves a relay of angiogenic cytokines that are released from interstitial mesenchymal cells, including VEGFA and angiopoietin1/2. [106] Furthermore, Shh-VEGF-Notch is an essential signal axis that dictates arterial EC identity and orchestrates intersegmental angiogenesis. [107] Studies using HUVEC or cardiac capillary EC documents a direct effect of Shh on angiogenic signaling, which activates noncanonical Shh signaling involving PI3K or RhoA activation. [108, 109] In skeletal ischemia or diabetic wound healing, activation of Shh-regulated angiogenesis program facilitates neovessel formation in the affected tissue. [110, 111] Cell therapy using CD34 + human HSPC overexpressing Shh demonstrates a salutatory effect on preserving cardiac function following acute myocardial infarction, which requires a paracrine effect of Shh-containing exosomes secreted from the transplanted CD34 + cells. [112] Interestingly, the absence of Shh pathway activation also paradoxically increases capillary density in the regenerated skeletal muscles of a murine hindlimb ischemia model. [113] Mechanistically, loss of Shh expression results in myocytes-induced macrophage infiltration, which secretes VEGFA to promote angiogenesis. [113] The differential effect of Shh on angiogenesis in tissue ischemia could be another example of achieving optimal signaling within a defined range of ligand concentration and/or mouse strain as well as vascular bed differences. PDGF-BB appears to be the upstream signal that induces Shh expression in an in vitro and in vivo corneal angiogenesis model. In this model, ERK1/2 and Akt are the two effectors that transduce the Shh signal. [114] conclusion Cholesterol metabolism has been shown to regulate angiogenesis, and future application of the insight gained from cholesterol-regulated angiogenesis, either alone or in combination with existing treatment regimens, may improve outcomes of patients in targeting pathological angiogenesis.
For example, since atorvastatin shows a biphasic effect on angiogenesis, would a period of a low dose treatment regimen benefit coronary artery disease patients to a greater extent? Would incorporating the information of S1P content on HDL contributes to a more effective treatment for cardiovascular disease? Targeting LXR is predicted to achieve dual salutary effects by impeding inflammation and restricting angiogenesis. AIBP is a particular protein of consideration for improving endothelial function because (1) it is an extracellular protein that is more amenable for targeting; (2) it effectively interferes with both angiogenesis and inflammation by enhancing HDL functionality; and (3) its depletion promotes functional angiogenesis that retains vascular integrity. Further investigation of the AIBP receptor and its role in AIBP-regulated angiogenesis will provide more therapeutic targets and guide development of new strategies for treatment of diseases associated with dysregulated angiogenesis.
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